The effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in the treatment of COVID-19 are highly debated. This study was aimed to assess aggregated risk by investigating the association of ACEIs/ARBs users against non-users of ACEIs/ARBs with the risk of mortality or severe clinical manifestations or magnitude of SARS-CoV-2 test positivity in COVID-19 patients. Systematic literature search was carried out in different databases for eligible studies. The pooled relative risks (RRs) were measured using RevMan software where P <0.05 was set as statistical significance. In total, 10 studies were included in this analysis. After pooled estimation, it was demonstrated that SARS-CoV-2 positive patients taking ACEIs/ARBs were not associated with an increased risk of mortality compared to those not taking ACEIs/ARBs (RR 0.89; 95% CI 0.64–1.23; P =0.48). Furthermore, the risk of composite severe clinical manifestations was not significantly different between the positive patients with or without ACEIs/ARBs users (RR 1.29; 95% CI 0.81–2.04; P =0.28). There was no risk difference for SARS-CoV-2 test positivity in patients with or without ACEIs/ARBs users (RR 1.00; 95% CI 0.95–1.05; P =0.91). These findings may augment current professional society guidelines for not discontinuing ACEIs/ARBs in treating COVID-19 patients where it is clinically indicated.
【저자키워드】 viral infection, Outcomes research, 【초록키워드】 COVID-19, Treatment, Mortality, risk, database, Patient, receptor, COVID-19 patients, association, angiotensin-converting enzyme inhibitor, Analysis, ACEIs, ARBs, clinical manifestation, 95% CI, no risk, increased risk, statistical significance, blocker, SARS-CoV-2 test, Effect, carried, indicated, clinically, demonstrated, magnitude, positive patient, were measured, eligible, not significantly different, RRs, SARS-CoV-2 positive patient, treating COVID-19 patient, 【제목키워드】 COVID-19, Meta-analysis, Mortality, severity, risk, angiotensin-converting enzyme inhibitor, blocker, SARS-CoV-2 test,